Summit Therapeutics Inc.

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
9.47 ^USD	+10.95%		+25.43%	+262.84%

01/07	Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell Small Cap Comp Value Index	CI
01/07	Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Growth Index	CI

Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell Small Cap Comp Value Index

July 01, 2024

Latest news about Summit Therapeutics Inc.

Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell Small Cap Comp Value Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Growth Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 3000 Value Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 2500 Value Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 2000 Value Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Growth Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 3000E Value Index	01/07	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Index	01/07	CI
Summit Therapeutics Inc. Enters into Two Sublease Agreements with Genius 24C Inc. and Duggan Investments Research LLC	28/06	CI
Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors	28/06	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	24/06	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	24/06	CI
Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP	18/06	CI
Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board	13/06	CI
Sector Update: Health Care Stocks Steady Premarket Monday	03/06	MT
Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	03/06	MT
Transcript : Summit Therapeutics Inc. - Special Call	03/06
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	03/06	MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	03/06	CI
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	03/06	CI
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	31/05	MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	31/05	MT
Sector Update: Health Care	31/05	MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	31/05	MT

Chart Summit Therapeutics Inc.

Duration

Period

More charts

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.293 GBP

Average target price

10.58 GBP

Spread / Average Target

+45.08%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SUMMIT THERAPEUTICS INC.	+262.84%	6.65B
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+25.27%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.64%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs